Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Down 16.3% in February

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 9,650,000 shares, a decline of 16.3% from the January 31st total of 11,530,000 shares. Approximately 7.7% of the shares of the company are sold short. Based on an average daily trading volume, of 1,270,000 shares, the days-to-cover ratio is presently 7.6 days.

Lyell Immunopharma Stock Performance

LYEL traded up $0.00 on Wednesday, reaching $0.71. The company had a trading volume of 232,494 shares, compared to its average volume of 1,086,316. The stock has a market cap of $206.85 million, a P/E ratio of -0.90 and a beta of -0.35. Lyell Immunopharma has a fifty-two week low of $0.51 and a fifty-two week high of $3.15. The company’s fifty day moving average is $0.62 and its 200 day moving average is $0.96.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC grew its stake in shares of Lyell Immunopharma by 7.4% in the fourth quarter. Barclays PLC now owns 258,380 shares of the company’s stock valued at $165,000 after acquiring an additional 17,765 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Lyell Immunopharma by 27.8% during the 4th quarter. Wells Fargo & Company MN now owns 94,320 shares of the company’s stock worth $60,000 after purchasing an additional 20,542 shares in the last quarter. Centiva Capital LP bought a new position in shares of Lyell Immunopharma during the third quarter worth approximately $31,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Lyell Immunopharma by 13.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after purchasing an additional 36,555 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of Lyell Immunopharma in the third quarter valued at approximately $52,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research report on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.